Immunogenicity of alternative and reduced immunization schedules using the thirteen-valent polysaccharide conjugate vaccine against infection with Streptococcus pneumoniae.
Phase of Trial: Phase IV
Latest Information Update: 27 Jun 2016
At a glance
- Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary)
- Indications Pneumococcal infections
- Focus Pharmacodynamics
- Acronyms PIM studie
- 04 Sep 2013 Results published in JAMA: the Journal of the American Medical Association.
- 16 Dec 2012 Status changed from planning to completed as reported by Netherlands Trial Register.
- 17 May 2010 New trial record